Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

China flag China · Delayed Price · Currency is CNY
35.92
+1.59 (4.63%)
Apr 29, 2026, 3:00 PM CST
28.25%
Market Cap 5.26B
Revenue (ttm) 449.50M
Net Income (ttm) 30.31M
Shares Out 146.32M
EPS (ttm) 0.21
PE Ratio 171.74
Forward PE n/a
Dividend 1.07 (3.12%)
Ex-Dividend Date n/a
Volume 2,051,614
Average Volume 1,745,150
Open 34.35
Previous Close 34.33
Day's Range 34.35 - 36.48
52-Week Range 27.26 - 50.98
Beta 0.65
RSI 55.36
Earnings Date Apr 25, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. In addition, the company is widely utilized across various medical institutions, judicial testing... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 622
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688767
Full Company Profile

Financial Performance

In 2025, Hangzhou Biotest Biotech's revenue was 448.01 million, a decrease of -19.91% compared to the previous year's 559.40 million. Earnings were 49.25 million, a decrease of -70.94%.

Financial Statements

News

There is no news available yet.